Fingolimod (FTY720) for Ischemic Stroke : A Mini Review

  • Shahram Ghiyasvand Kidney Research Center, Tabriz University of Medical Sciences, Tabriz Iran
  • Sepideh Zununi Vahed Kidney Research Center, Tabriz University of Medical Sciences, Tabriz Iran
  • Mohammadreza Ardalan Kidney Research Center, Tabriz University of Medical Sciences, Tabriz Iran
DOI: https://doi.org/10.13183/jecns.v7i1.108

Abstract

Brain Ischemic events abruptly start an expanding wave of cytokines release and oxidative stress within the brain tissue. This inflammatory storm alters the permeability of brain blood barrier (BBB,), up regulates the endothelial cell adhesion molecules (ICAMs) and causing intense inflow of inflammatory cells toward the ischemic brain.  This inflammatory phase further exacerbates the brain damage. In a second phase, after a few days, brain, via intense noradrenergic discharge targets the peripheral immune system and create general immunosuppression to protect itself from inflammation. Fingolimod (FTY720) a high-affinity agonist of sphingosine-1-phosphate (S1P) prevents S1P mediated lymphocytes migration from lymph node toward the systemic circulation and finally to the brain during the early phase of ischemic stroke.  

Published
2019-12-27
Issue
Vol 7 No 1 (2020)
Section
Mini Review Article

Copyright (c) 2020 Shahram Ghiyasvand, Sepideh Zununi Vahed, Mohammadreza Ardalan

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles published in J Exp Clin NeuroSci are licensed under a Creative Commons Attribution 4.0 International License.
The journal allows the author(s) to hold and retain the copyright without restrictions.